Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3834757 | 0.81 | RAPGEF4 (0.65) | RAPGEF4CA1CA2L3MBTL1POLB | |
| SCHEMBL3188642 | 0.79 | RAPGEF4 (0.61) | RAPGEF4CA1CA2L3MBTL1POLB | |
| SCHEMBL7641128 | 0.79 | RAPGEF4 (0.61) | RAPGEF4CA1CA2L3MBTL1POLB | |
| SCHEMBL5535689 | 0.79 | RAPGEF4 (0.61) | RAPGEF4CA1CA2L3MBTL1POLB | |
| SCHEMBL1365792 | 0.79 | RAPGEF4 (0.61) | RAPGEF4CA1CA2MAPTL3MBTL1 | |
| SCHEMBL2457308 | 0.76 | RAPGEF4 (0.58) | RAPGEF4CA1CA2L3MBTL1POLB | |
| SCHEMBL15175998 | 0.76 | RAPGEF4 (1.00) | RAPGEF4CA1CA2L3MBTL1POLB | |
| SCHEMBL29001261 | 0.75 | CA1 (0.59) | RAPGEF4CA1CA2L3MBTL1POLB | |
| SCHEMBL1770928 | 0.75 | MMP2 (0.58) | RAPGEF4CA1CA2L3MBTL1POLB | |
| SCHEMBL16540512 | 0.75 | RAPGEF4 (0.56) | RAPGEF4CA1CA2L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478620-B2 | Cyano-substituted cyclic hydrazine derivative and application thereof | E-NITIATE BIOPHARMACEUTICALS (HANGZHOU) CO., LTD (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20220339146-A1 | CYANO-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF | E-NITIATE BIOPHARMACEUTICALS (HANGZHOU) CO., LTD (CN) | 2022-10-27 | — | — | US | disclosed |
| EP-4032888-A1 | CYANO-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) | 2022-07-27 | — | — | EP | disclosed |
| CN-110483514-B | Cyano-substituted cyclic hydrazine derivative and application thereof | 启元生物(杭州)有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3856742-A1 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339146-A1 | CYANO-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF | WNK1, STK35, CDK1 | RAPGEF4 3213/4885CA1 276/4885CA2 185/4885 |
| US-12478620-B2 | Cyano-substituted cyclic hydrazine derivative and application thereof | WNK1, STK35, CDK1 | RAPGEF4 3213/4885CA1 276/4885CA2 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.